Research Working Group      Policy Development Working Group      International Affairs Working Group

Linking Researchers and Industry

  • The Avicenna Alliance is dedicated to ensuring the full innovation cycle of predictive medicine is represented.
  • The Virtual Physiological Human (VPH) Initiative, carries a non-diminishable 50% board representation on the Avicenna Alliance with Industry representatives from Medical Devices, Pharmaceuticals and Software also maintaining a 50% board membership.
  • The VPH Institute is a massive network of Research Organisations and Universities engaged in predictive or in silico medicine.
  • The VPH institute has its origins in a European Commission endorsed research area on computer modeling and simulation and has been active for over 10 years.
  • This partnership of industry and researchers allows the Avicenna Alliance to address challenges to the predictive or in silico market from pre-clinical research all the way to post-market. 

Avicenna Alliance news

Dassault to enhance clinical tech with Medidata acquisition

Dassault Systèmes acquired Medidata, major player in information technologies for clinical trials, for $5.5 billion. This represents to...

find out more ›

Promote adoption of In Silico Trials through EMA’s strategy on Regulatory Science to 2025

The European Medicine Agency (EMA) has recently published a document that describes its strategy until 2025....

find out more ›

European Strategy for High Performance Computing

On the 17 June, the European Commission published a presentation explaining why they indicated High Performance Computing (HPC) as a priority area for...

find out more ›

Show all activites